A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.

Monica M MitaPatricia M LoRussoKyriakos P PapadopoulosMichael S GordonAlain C MitaRoberta FerraldeschiHarold KeerAram OganesianXiang Yao SuSimone JueligerAnthony W Tolcher

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

ASTX660 demonstrated a manageable safety profile and exhibited evidence of pharmacodynamic and preliminary clinical activity at the 180-mg/day RP2D. The phase II part of the study is ongoing.

Keyphrases

phase ii
clinical trial
oxidative stress
open label
endoplasmic reticulum stress
randomized controlled trial
diffuse large b cell lymphoma
cell death
signaling pathway
young adults
placebo controlled